DENVER, Colo., Oct 5, 2023 (www.247marketnews.com)- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) stated, this morning, that it is exploring strategic alternatives and plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of Company assets, a sale of all of the Company, a merger or other strategic transactions. As the Company engaged Moelis & Company to explore strategic options and expects to conduct this process over the remainder of 2023. Impel will continue to provide full commercial support behind Trudhesa, including Trudhesa Direct access support.
Impel Pharmaceuticals is trading at $0.4399, up $0.0289 (+7.03%), on 102.2K premarket shares traded.
Its 52-week range is $0.18 to $2.962. It had a massive trading volume session, yesterday, which will become today’s inflection points, but, if it can match yesterday’s volume, it may make a special move.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
